Search results for "ddc:6"

showing 10 items of 788 documents

Overview of the DEMO staged design approach in Europe

2019

This paper describes the status of the pre-conceptual design activities in Europe to advance the technical basis of the design of a DEMOnstration Fusion Power Plant (DEMO) to come in operation around the middle of this century with the main aims of demonstrating the production of few hundred MWs of net electricity, the feasibility of operation with a closed-tritium fuel cycle, and maintenance systems capable of achieving adequate plant availability. This is expected to benefit as much as possible from the ITER experience, in terms of design, licensing, and construction. Emphasis is on an integrated design approach, based on system engineering, which provides a clear path for urgent R&D …

Nuclear and High Energy Physicsbreeding blanket; DEMO; design integration; divertor; fusion reactor; systems codeDesign activitiesFuel cyclemedia_common.quotation_subjectThermal power stationDesign integration7. Clean energy01 natural sciences010305 fluids & plasmasdesign integration0103 physical sciencesdivertorProduction (economics)010306 general physicsDEMOmedia_commonbreeding blanketIntegrated designbusiness.industryCondensed Matter PhysicsInterdependencesystems codeSystems engineeringfusion reactorElectricityddc:620businessNuclear Fusion
researchProduct

Measuring the isotope effect on the gross beryllium erosion in JET

2022

Abstract The isotope effect, hydrogen (H) versus deuterium (D), on the gross beryllium (Be) erosion yield has been measured in ohmic limiter plasmas in JET tokamak by spectroscopic means. A simplified method to extract the effective sputtering yield from the quotient of the radiances of the D α or D γ and the Be II lines at 527 nm was applied. A clear isotope effect has been found, the erosion yield of D being about a factor of 2 larger compared to H in the whole explored plasma density range. This is in agreement with physical sputtering data obtained with H+ and D+ ion beams and also with material surface computer simulations. The already published contribution of chemically assisted phys…

Nuclear and High Energy PhysicsspectroscopyJETsputteringddc:620Condensed Matter Physicsberylliumerosionisotopelimiter
researchProduct

Learning from foreign operation modes: The virtuous path for innovation

2020

In this article, we analyze the impact of learning from internationalization on small and medium enterprises’ (SMEs) performance along different development paths. Drawing on the exploitation versus exploration logic, we use an alternative view of foreign operation modes (the learning perspective) to provide insights into the impact of such learning on technological and organizational innovation as well as overall performance. Our results, which are derived from a sample of 132 SMEs active in traditional manufacturing industries, point to a path to superior performance that entails resource-augmenting operation modes and organizational innovation. JEL CLASSIFICATION: O31; F23; L25; M10; M1…

O31Economics and EconometricsL25Strategy and Management05 social sciencesM10operation modeExploitationexplorationGeneral Business Management and AccountingM16innovationInternationalizationorganizational learning0502 economics and businessPath (graph theory)ddc:650050211 marketingSmall and medium-sized enterprisesBusinessF23Business and International Management050203 business & managementIndustrial organization
researchProduct

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ER…

2020

Guidelines summarize and evaluate available evidence with the aim of assisting health professionals in proposing the best management strategies for an individual patient with a given condition. Guidelines and their recommendations should facilitate decision making of health professionals in their daily practice. However, the final decisions concerning an individual patient must be made by the responsible health professional(s) in consultation with the patient and caregiver as appropriate.

ORAL ANTICOAGULANT-THERAPYdiagnosis[SDV]Life Sciences [q-bio]Medizin030204 cardiovascular system & hematologyEmbolectomyGuidelineRECURRENT VENOUS THROMBOEMBOLISM0302 clinical medicinePregnancyDaily practiceDiagnosisPulmonary medicineVenous thrombosisPulmonary MedicineThrombolytic TherapyDEEP-VEIN THROMBOSISDisease management (health)Societies MedicalComputingMilieux_MISCELLANEOUShealth care economics and organizationsRisk assessmentddc:616RIGHT-VENTRICULAR DYSFUNCTIONDisease ManagementShockMOLECULAR-WEIGHT HEPARINThrombolysishumanities3. Good healthPulmonary embolismEuropeAnticoagulation; Biomarkers; Diagnosis; Dyspnoea; Echocardiography; Embolectomy; Guidelines; Heart failure; Pregnancy; Pulmonary embolism; Right ventricle; Risk assessment; Shock; Thrombolysis; Treatment; Venous thromboembolism; Venous thrombosismedicine.veinEchocardiographyAcute DiseaseRight ventricleMedical emergencyCardiology and Cardiovascular MedicineRisk assessmentguidelines; pulmonary embolism; venous thrombosis; shock dyspnoea; heart failure: right ventricle: diagnosis; risk assessment: echocardiography; biomarkers; treatment; anticoagulation; thrombolysis; pregnancy; venous thromboembolism; embolectomyDiagnosiVenous thromboembolismthrombolysiseducationCardiologyMEDLINEThrombolysiHeart failure610 Medicine & healthGuidelinesInferior vena cava2705 Cardiology and Cardiovascular MedicineEXTRACORPOREAL MEMBRANE-OXYGENATION03 medical and health sciencesAnticoagulationMedicalDyspnoeamedicineHumansRIGHT HEART THROMBIVENTILATION-PERFUSION SCINTIGRAPHYshock dyspnoeaHealth professionalsbusiness.industryINFERIOR VENA-CAVA10031 Clinic for Angiologyheart failure: right ventricle: diagnosisPulmonary embolismAnticoagulantsbiomarkersrisk assessment: echocardiography030229 sport sciencesBiomarkermedicine.diseaseTreatmentINHALED NITRIC-OXIDESocietiesbusinessBiomarkers
researchProduct

Type A competitiveness traits correlate with downregulation of c-Fos expression in patients with type 1 diabetes.

2019

International audience; AimType A personality has been associated with increased survival in people with type 1 diabetes (T1D). Systemic low-grade inflammation may play a critical role, as suggested in recent reports, although the links between the inflammatory circulating transcriptome and Type A remain unknown. This prompted our exploration of the potential associations between Type A personality and c-Fos gene expression, a candidate gene closely linked to inflammatory processes, in T1D.MethodsType A personality was assessed by Bortner questionnaire in patients with T1D, and two subscales – ‘speed’ and ‘competitiveness’ – were used to measure these specific dimensions of Type A. Expressi…

OncologyAdultMalemedicine.medical_specialtyCandidate geneInverse AssociationCompetitive BehaviorEndocrinology Diabetes and MetabolismDown-RegulationGene Expression030209 endocrinology & metabolismPilot Projects030204 cardiovascular system & hematologyType ATranscriptomeCohort Studies03 medical and health sciencesddc:616.890302 clinical medicineEndocrinologyInternal medicineGene expressionInternal MedicinemedicineHumansGene[SDV.MHEP.EM] Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismInflammationType 1 diabetesc-FosBlood Cellsbusiness.industryGene Expression ProfilingDiabetesType A and Type B personality theoryType A PersonalityGeneral Medicine[SDV.MHEP.EM]Life Sciences [q-bio]/Human health and pathology/Endocrinology and metabolismMiddle Agedmedicine.diseaseCompetitivenessDiabetes Mellitus Type 1businessBody mass indexProto-Oncogene Proteins c-fosDiabetic AngiopathiesPersonalityDiabetesmetabolism
researchProduct

A multicenter DeCOG study on predictors of vemurafenib therapy outcome in melanoma: pretreatment impacts survival

2015

Background: Kinase inhibitors targeting the BRAF V600 mutation have become standard in the treatment of metastatic melanoma. Albeit in wide clinical use, the patterns associated with therapy outcome are not fully elucidated. The present study was aimed to identify predictive factors of therapy response and survival under the BRAF inhibitor vemurafenib. Patients and methods: This multicenter retrospective study analyzed patient, tumor, and pretreatment characteristics collected in BRAF V600-mutated stage IV melanoma patients before single-agent therapy with the BRAF inhibitor vemurafenib. Results: A total of 300 patients from 14 centers were included into this study with a median follow-up t…

OncologyAdultMalemedicine.medical_specialtyIndolesSkin Neoplasmsmedicine.medical_treatmentMedizin-Disease-Free Survival03 medical and health sciences0302 clinical medicineMedizinische FakultätInternal medicinemedicineHumansddc:610VemurafenibMelanoma030304 developmental biologyRetrospective Studies0303 health sciencesChemotherapySulfonamidesbusiness.industryMelanomaHazard ratioRetrospective cohort studyHematologyImmunotherapyMiddle Agedmedicine.diseaseChemotherapy regimen3. Good healthTreatment OutcomeOncologyVemurafenib030220 oncology & carcinogenesisCancer researchFemalebusinessV600Emedicine.drug
researchProduct

Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitor…

2020

Introduction Cancer patients tend to prefer oral instead of parenteral chemotherapy. To date, there is little evidence on the medication adherence in cancer patients. We investigated medication adherence to tyrosine kinase inhibitors in patients suffering from non-small cell lung cancer. Methods Tyrosine kinase inhibitor adherence was measured electronically by MEMS® (medication event monitoring system) over at least six months. Adherence rates were calculated in terms of Dosing Compliance, Timing Compliance, Taking Compliance, and Drug Holidays. Patients were dichotomized as adherent when Dosing Compliance and Timing Compliance were ≥80%, Taking Compliance ranged between 90 and 110%, and &…

OncologyAdultMalemedicine.medical_specialtyLung Neoplasmsmedicine.drug_classmedicine.medical_treatmentTyrosine-kinase inhibitorMedication Adherence03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineCarcinoma Non-Small-Cell LungmedicineHumansPharmacology (medical)ddc:610030212 general & internal medicinePatient Reported Outcome MeasuresProspective StudiesLung cancerAdverse effectProtein Kinase InhibitorsAgedAged 80 and overChemotherapybusiness.industryCancerMiddle AgedProtein-Tyrosine Kinasesmedicine.diseaseOncology030220 oncology & carcinogenesisQuality of LifeObservational studyFemalebusinessTyrosine kinaseJournal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners
researchProduct

Is APOE ε4 associated with cognitive performance in early MS?

2020

ObjectiveTo assess the impact of APOE polymorphisms on cognitive performance in patients newly diagnosed with clinically isolated syndrome (CIS) or relapsing-remitting MS (RRMS).MethodsThis multicenter cohort study included 552 untreated patients recently diagnosed with CIS or RRMS according to the 2005 revised McDonald criteria. The single nucleotide polymorphisms rs429358 (ε4) and rs7412 (ε2) of the APOE haplotype were assessed by allelic discrimination assays. Cognitive performance was evaluated using the 3-second paced auditory serial addition test and the Multiple Sclerosis Inventory Cognition (MUSIC). Sum scores were calculated to approximate the overall cognitive performance and memo…

OncologyApolipoprotein Emedicine.medical_specialtyClinically isolated syndromemedicine.diagnostic_testPaced Auditory Serial Addition Testbusiness.industryMultiple sclerosisCognitionMcDonald criteria610 Medicine & healthmedicine.diseaseNeurologyInternal medicinemedicineddc:610Neurology (clinical)Effects of sleep deprivation on cognitive performance610 Medicine & healthFunction and Dysfunction of the Nervous SystembusinessCohort study
researchProduct

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing live…

2010

Abstract Background The potential anti-cancer effects of mammalian target of rapamycin (mTOR) inhibitors are being intensively studied. To date, however, few randomised clinical trials (RCT) have been performed to demonstrate anti-neoplastic effects in the pure oncology setting, and at present, no oncology endpoint-directed RCT has been reported in the high-malignancy risk population of immunosuppressed transplant recipients. Interestingly, since mTOR inhibitors have both immunosuppressive and anti-cancer effects, they have the potential to simultaneously protect against immunologic graft loss and tumour development. Therefore, we designed a prospective RCT to determine if the mTOR inhibito…

OncologyCancer ResearchTime Factorsmedicine.medical_treatmentMedizinIntracellular Signaling Peptides and Proteins - antagonists & inhibitors metabolismKaplan-Meier Estimate312 Clinical medicineProtein-Serine-Threonine KinaseLiver transplantationTHERAPYStudy ProtocolImmunosuppressive Agentendothelial growth-factor renal-cell carcinoma tumor progression rapamycin cancer cyclosporine efficacy therapy target model0302 clinical medicineRENAL-CELL CARCINOMARisk FactorsRecurrenceSurgical oncologyMedicine and Health SciencesLiver Neoplasms - drug therapy enzymology mortality surgerySirolimuProspective StudiesTUMOR PROGRESSIONTransplantation Homologoueducation.field_of_studyliver transplantationTOR Serine-Threonine KinasesLiver NeoplasmsIntracellular Signaling Peptides and ProteinsImmunosuppressionhepatocellular carcinomalcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCANCER3. Good healthEuropeMulticenter StudyTreatment OutcomeTARGETsirolimusOncologyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinomaRandomized Controlled TrialmTORCarcinoma Hepatocellular - drug therapy enzymology mortality surgery030211 gastroenterology & hepatologyImmunosuppressive AgentsRCTHumanmedicine.drugCanadamedicine.medical_specialtyCarcinoma HepatocellularTime FactoreducationPopulationLiver Transplantation - adverse effects mortalityProtein Serine-Threonine Kinaseslcsh:RC254-282Disease-Free Survival03 medical and health sciencesInternal medicineGeneticsmedicineTransplantation HomologousHumansComparative StudyRapamycinddc:610educationProtein-Serine-Threonine Kinases - antagonists & inhibitors metabolismKaplan-Meiers Estimatebusiness.industryRisk FactorAustraliaImmunosuppressive Agents - therapeutic useSirolimus - therapeutic useEFFICACYHumans; Liver Transplantation; Hepatocellular Carcinoma; Randomized Controlled Trial; RCT; Multicenter Study; Comparative Study; Rapamycin; mTOR; Sirolimusmedicine.diseaseSurgeryMODELTransplantationClinical trialProspective StudieIntracellular Signaling Peptides and ProteinSirolimusENDOTHELIAL GROWTH-FACTORCYCLOSPORINERAPAMYCINbusiness
researchProduct

Progression-free survival as a surrogate for overall survival in advanced/recurrent gastric cancer trials: a meta-analysis.

2013

The traditional endpoint for assessing efficacy of chemotherapies for advanced/recurrent gastric cancer is overall survival (OS), but OS requires prolonged follow-up. We investigated whether progression-free survival (PFS) is a valid surrogate for OS. Using individual patient data from the GASTRIC meta-analysis, surrogacy of PFS was assessed through the correlation between the endpoints and through the correlation between the treatment effects on the endpoints. External validation of the prediction based on PFS was also evaluated. Individual data from 4069 patients in 20 randomized trials were analyzed. The rank correlation coefficient between PFS and OS was 0.853 (95% confidence interval […

OncologyCancer Researchmedicine.medical_specialtyBioinformaticsBrief CommunicationDisease-Free Survivallaw.inventionRandomized controlled triallawPredictive Value of TestsStomach NeoplasmsInternal medicinemedicineOdds RatioHumansProgression-free survivalRandomized Controlled Trials as Topicddc:616Surrogate endpointbusiness.industryOdds ratioChemotherapy regimenConfidence intervalTreatment OutcomeOncologyPredictive value of testsMeta-analysisNeoplasm Recurrence LocalbusinessBiomarkersJournal of the National Cancer Institute
researchProduct